SBC Medical Group Holdings Incorporated Stock Price, News & Analysis

SBC Medical Group Holdings (Nasdaq: SBC) announced the launch of its new brand, "Hada no Aozora Clinic", set to open in Tokyo on October 1, 2025. The clinic will implement a hybrid dermatology model combining insurance-covered general dermatology with private-pay aesthetic treatments.

The expansion comes amid significant growth in non-surgical procedures in Japan, which increased from 1.62 million in 2017 to 3.06 million in 2024, representing 88% of total aesthetic treatments. SBC Medical, which operates over 250 clinics globally with six million annual patient visits, aims to leverage its experience in both private-pay and insurance-based care to maintain an efficient, low-cost operating model.

SBC Medical (NASDAQ:SBC), a global provider of medical consulting and management services, has announced its participation in two major investor conferences in September 2025.

The company will present at the H.C. Wainwright Conference on September 8, with Head of IR Hikaru Fukui as the main speaker. Additionally, Director, CFO, and COO Yuya Yoshida will deliver a presentation at the Emerging Growth Conference on September 25 from 9:05 - 9:35 AM ET. During these events, SBC Medical will conduct one-on-one meetings with institutional investors.

SBC Medical Group (NASDAQ:SBC) has appointed Dr. Ewen Chee as President of Aesthetic Healthcare Holdings (AHH) and Lead Doctor for Asia Strategy. Dr. Chee, founder of Singapore's leading aesthetic medical company AHH and The Chelsea Clinic, brings over 20 years of clinical experience in aesthetic medicine.

Dr. Chee will focus on physician recruitment and training across the Asia-Pacific region. He is a certified physician of the American Academy of Aesthetic Medicine (AAAM) and has served as Co-Chair of the Asia-Pacific Thread Lift Meeting (APEM). His expertise spans various treatments including fillers, lasers, botulinum toxin, and thread lifts.

The appointment aims to leverage Singapore's position as the "Aesthetic Medicine Hub of Asia" and establish a scalable platform for SBC's expansion in the region.

SBC Medical Group (NASDAQ: SBC) reported challenging Q2 2025 financial results, with significant year-over-year declines across key metrics. Total revenue decreased 18% to $43 million, while net income fell 87% to $2.5 million. Earnings per share dropped to $0.02 from $0.20 in Q2 2024.

Despite financial headwinds, the company demonstrated operational growth with 259 franchise locations (up 36 locations YoY) and served 6.31 million customers (14% increase YoY) with a strong 72% repeat rate. The decline in financial metrics was primarily attributed to strategic shifts, including the discontinuation of staffing services, targeted divestitures, and fee structure revisions.

Management remains focused on optimizing their franchise model and transitioning to higher-margin operations despite challenges in Japan's consumer discretionary market.

SBC Medical Group Holdings (NASDAQ: SBC) reported its Q2 2025 financial results, showing significant year-over-year declines across key metrics. Total revenue decreased 18% to $43 million, while net income fell 87% to $2.5 million. EPS dropped to $0.02 from $0.20 in Q2 2024.

The company's strategic restructuring initiatives included discontinuing its staffing business, completing targeted divestitures, and revising its fee structure. Despite the financial downturn, SBC Medical expanded its franchise network to 259 locations and served 6.31 million customers in the last twelve months, achieving a 72% customer repeat rate.

For H1 2025, total revenues were $91 million (down 16% YoY), with net income of $24 million (down 36% YoY) and EBITDA of $40 million (down 25% YoY).

SBC Medical (NASDAQ:SBC), a global aesthetic clinic services provider, has scheduled its Q2 2025 financial results announcement for August 13, 2025, before U.S. market opening. The company will host a conference call at 8:30 AM ET on the same day to discuss results and take questions.

Participants must pre-register through the provided link to access the conference call viewing site, which will feature presentation materials 10 minutes before the call. The presentation replay will remain accessible until August 13, 2026, with materials available for download on the company's IR website.

SBC Medical Group (Nasdaq: SBC) has acquired MB career lounge, a Japanese provider of management support services for medical institutions, through a cash transaction. The deal includes JUN CLINIC, a network of aesthetic clinics across multiple Japanese locations including Shirokane, Ginza, and Nagano.

The acquisition strengthens SBC Medical's position in Japan's growing aesthetic medicine market, which reached ¥631 billion in 2024 with 6.2% year-over-year growth. JUN CLINIC, known for its personalized treatment approach including laser therapies and injectables, operates under board-certified dermatologist supervision and serves as a certified facility for the Customized Treatment Study Group.

This strategic move aims to accelerate regional expansion, diversify service offerings, and reduce reliance on single procedures or geographical areas.

SBC Medical (NASDAQ:SBC) has appointed renowned plastic and craniofacial surgeon Dr. Steven R. Cohen as Medical Strategy Advisor to accelerate its global expansion initiatives. Dr. Cohen, founder of Faces+ and recognized by Newsweek as one of "America's Best Plastic Surgeons," brings over 30 years of clinical experience and significant innovations in regenerative aesthetics.

Following its Nasdaq listing in September 2024, SBC Medical aims to leverage Dr. Cohen's expertise to enhance medical quality, strengthen international brand positioning, expand academic collaborations, and improve physician training programs. Dr. Cohen, a Clinical Professor at UC San Diego, is known for inventing the internal craniofacial distraction device and LipoCube, which have become global industry standards.

SBC Medical Group Holdings (NASDAQ: SBC), a global aesthetic clinic services provider, has appointed Shinya Inoue as its new Chief Marketing Officer (CMO), effective July 1, 2025. In his role, Inoue will focus on enhancing the brand value of the group's portfolio, including Shonan Beauty Clinic, and optimizing the company's marketing infrastructure with an emphasis on digital innovation.

Inoue brings extensive experience from prominent companies including P&G Japan, Eli Lilly Japan, Adobe, and KDDI. Most recently, he served as CMO at Pioneer Corporation, where he led marketing organization initiatives and new product launches. His expertise spans brand strategy, organizational management, and integrated digital marketing.

The appointment follows SBC Medical's Nasdaq listing last year and aligns with the company's mission to make aesthetic medicine more accessible since opening its first clinic in Fujisawa in 2000.